Fig. 10From: Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancerCorrelation between XRCC4 expression and the drug sensitivity across cancer types. A By CellMiner, B By GDSC and C by CTRPBack to article page